The industry may not be ready for India and China as regulatory issues emerge.
Outsourcing is weighing in more as a tactic for cost-cutting, but it is still not the primary weapon.
BioPlan's Annual Report shows continued growth in the use of single-use technology.
BioPlan's outsourcing survey gives insight on top activities, budgets, and growth trends in biopharmaceutical outsourcing.
Growth is seen in outsourcing of insect- and plant-cell-based bioproduction expression systems.
Will international biomanufacturing outsourcing become mainstream in this decade?
Budgets for biopharma activities are gaining in select functional areas, except outsourcing.
Industry wants more innovation, but can suppliers meet customers' needs?
New outsourcing industry sectors have become multibillion-dollar industries.
Industry optimism is on the rise for 2012.